Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Minister Nudges Generic Product Consolidation, Pitches “5 Makers per API”
July 5, 2024
-
BUSINESS 32 Pharma Execs Snag 100 Million Yen-Plus in FY2023, Takeda Sweeps Top 3
July 4, 2024
-
BUSINESS Chugai Grabs Japan’s Best-Paying Pharma Crown Yet Again: Jiho Tally
July 3, 2024
-
REGULATORY New ICH Topic on RWD to Be Proposed towards Its Use in Regulatory Review
July 2, 2024
-
REGULATORY PMDA Opens 1st Overseas Office in Bangkok
July 2, 2024
-
BUSINESS Eisai to Go Solo on Its 1st ADC after BMS Exits Deal
July 2, 2024
-
BUSINESS Pfizer Files Hemophilia B Gene Therapy in Japan
July 1, 2024
-
REGULATORY MHLW Sets Up Global Strategy HQ to Bolster Innovation Ecosystem
June 28, 2024
-
BUSINESS Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
June 27, 2024
-
BUSINESS Finnish Pharma Orion Poised for Japan Debut with Reacquisition of Parkinson’s Meds This Year
June 26, 2024
-
BUSINESS BMS Gears Up for Return to Neuroscience with KarXT, Explores Path toward Japan Rollout Too
June 25, 2024
-
REGULATORY Japan OKs Honebuto Paper, Modest Wording on Off-Year Revisions Finalized
June 24, 2024
-
ACADEMIA Academic Society Frets Availability of 1st-Gen Oral Cephems amid Choseido Halt
June 24, 2024
-
REGULATORY Japan to Obligate Single IRB in Multi-Center Clinical Trials That Use Competitive Funds
June 24, 2024
-
BUSINESS Axcelead’s Next CEO Eyes Sales of 120 Billion Yen, Ramp-Up in Mega Pharma Orders
June 21, 2024
-
BUSINESS SanBio Says Its Lead Cell Therapy Could Be Shipped from 2025 If All Goes Well
June 21, 2024
-
BUSINESS Gilead Eager to See More Authorized CAR-T Treatment Centers in Japan
June 21, 2024
-
BUSINESS Tsumura Looks to Plant “Guidepost” for Development of Botanical Drugs in US
June 20, 2024
-
REGULATORY SanBio’s Lead Cell Therapy in Line for Conditional Nod but Can’t Be Shipped Until Comparability Is Confirmed
June 20, 2024
-
BUSINESS Concerns Grow over Supply of Cephem Antibiotics after Choseido Plant Halt
June 19, 2024
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…